Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs

Viola, Marinella; Quaratino, Donato; Volpetti, Sabrina; Gaeta, Francesco; Romano, Antonino

doi:10.1016/j.jaci.2006.02.011

Cited by 19 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to our study population, 27 of the 31 patients whom we evaluated had also participated in a previous study of ours regarding tolerability of parecoxib, published as a letter [13]. We studied them because they constituted an available sample of subjects with well-demonstrated NSAID hypersensitivity.…”

Section: Discussionmentioning

confidence: 99%

“…Twenty-seven of the 31 patients of the present study had also participated in a previous study of ours [13] regarding tolerability of parecoxib in patients with well-established NSAID hypersensitivity, and all 27 subjects had tolerated this drug.…”

Section: Methodsmentioning

confidence: 99%

“…Nimesulide and meloxicam, preferential inhibitors of COX-2 (the induced isoform), can often be safely administered to NSAID-sensitive patients [7, 8]. The newer NSAIDs, such as rofecoxib, celecoxib, valdecoxib, parecoxib and etoricoxib, which selectively inhibit COX-2 without affecting the arachidonic acid metabolism [5], showed no clinical crossreactivity and can be considered good alternatives for patients with hypersensitivity to nonselective NSAIDs [5,9,10,11,12,13]. However, selective NSAIDs may provoke hypersensitivity reactions in a minority of patients, particularly in those with cutaneous reactions, with a frequency ranging from 1.6% for rofecoxib to 11.1% for celecoxib [14].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Etoricoxib Tolerability in Patients with Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs

Viola¹,

Quaratino²,

Gaeta³

et al. 2007

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly observed, particularly among patients with chronic urticaria or asthma. The identification of a safe and reliable alternative is a frequent problem in clinical practice. Our aim was to investigate the clinical tolerability of etoricoxib, a new selective cyclooxygenase-2 inhibitor, in a group of patients with well-established NSAID hypersensitivity. Methods: We assessed 31 adults (21 women and 10 men) who reported one or more adverse reactions to NSAIDs, manifested as cutaneous, respiratory or anaphylactic symptoms. Sixteen of them reported reactions to a single NSAID (single reactors) and 15 to more than one NSAID (multiple reactors); the most frequently involved drug was acetylsalicylic acid. First, each patient underwent allergologic tests (skin and/or oral challenge tests) with culprit NSAIDs and then tolerability tests with increasing doses of etoricoxib up to 120 mg. All challenges were performed under single-blind, placebo-controlled conditions. Results: NSAID hypersensitivity was diagnosed in all 31 patients: 3 displayed positive results to pyrazolone skin tests and the other 28 to challenges with culprit NSAIDs. None reacted to either placebos or etoricoxib. Conclusions: Etoricoxib seems to be a safe alternative for patients with well-demonstrated NSAID hypersensitivity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Etoricoxib Tolerability in Patients with Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs

Viola¹,

Quaratino²,

Gaeta³

et al. 2007

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

show abstract

“…These results agree with the data published by Colanardi et al [7], who tested parecoxib parenterally in a group of 79 NSAID-induced urticaria/angioedema subjects and demonstrated its good tolerance in all patients. Another study previously published by Viola et al [6] also demonstrated the good tolerance of parecoxib administered intravenously in patients with NSAID hypersensitivity. However, only 5 out of 27 patients studied presented respiratory symptoms with NSAIDs.…”

Section: Discussionmentioning

confidence: 67%

“…Its safety in patients with NSAID sensitivity has been demonstrated in 2 studies, but only few asthmatic patients with AERD were evaluated [6,7]. Recently, a report on 2 asthma patients without previously confirmed AERD suffering severe bronchospasm after the administration of parecoxib indicated its potential risk [8].…”

Section: Introductionmentioning

confidence: 99%

Safety of Parecoxib in Asthmatic Patients with Aspirin-Exacerbated Respiratory Disease

Valero

Sánchez-López

Bartra

et al. 2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Aspirin-exacerbated respiratory disease (AERD) affects a subset of patients with asthma. Cyclooxygenase 2 inhibitors are a safe alternative in patients with AERD. Parecoxib is the first cyclooxygenase 2 selective drug for parenteral administration, especially useful after surgery thanks to its analgesic power. The aim of the study is to assess the tolerance of parecoxib (Dynastat®; Pfizer) given by intramuscular route in patients with AERD. Methods: Patients evaluated were referred to the Pneumology and Respiratory Allergy Department of the Hospital Clinic (Barcelona, Spain) for asthma exacerbations precipitated by 2 or more different non-steroidal anti-inflammatory drugs (NSAIDs). AERD was confirmed by a nasal challenge test with aspirin. Patients were challenged with parecoxib, and urine samples were collected to measure the leukotriene E₄ concentration. Results: Ten patients were challenged with parecoxib. No symptoms were reported with any of the administered doses, and there were no signs of immediate or delayed hypersensitivity. There were no alterations in the forced expiratory volume in 1 s or in acoustic rhinometry measurements. No significant differences between leukotriene E₄ levels were detected. Conclusion: The drug was well tolerated by all patients, with no adverse reactions. This lack of reactions found in our study supports the fact that parecoxib could be a safe alternative in postsurgery analgesia in NSAID-intolerant asthma patients.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2006

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs

Cited by 19 publications

References 11 publications

Etoricoxib Tolerability in Patients with Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs

Etoricoxib Tolerability in Patients with Hypersensitivity to Nonsteroidal Anti-Inflammatory Drugs

Safety of Parecoxib in Asthmatic Patients with Aspirin-Exacerbated Respiratory Disease

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About